You are here
About the shortages of Vyvanse (lisdexamfetamine dimesilate) capsules
Takeda Pharmaceuticals Australia has notified us that there will be limited availability of some strengths of Vyvanse (lisdexamfetamine dimesilate). These shortages affect Vyvanse products as follows:
Estimated return to normal supply
Vyvanse 30 mg
7 March 2024
Vyvanse 40 mg
30 April 2024
Vyvanse 50 mg
7 March 2024
Vyvanse 60 mg
19 April 2024
Vyvanse 20 mg and 70 mg strengths are not currently impacted.
The details of these shortages and how long they may last can change. This page will be updated if Takeda notifies us of any changes to this shortage situation. Please also refer to the Medicine Shortage Reports Database (search for ‘Vyvanse’) for the most up-to-date information.
Takeda has advised that the current shortages have been caused by manufacturing delays compounded by increased demand. While Takeda is expecting some deliveries during this period, these are not expected to satisfy demand for all strengths.
Vyvanse is used to treat serious conditions such as attention deficit hyperactivity disorder (ADHD) and binge eating disorder (BED). We understand the difficulties shortages of this medicine will cause, and we are responding to this issue as a priority. We are working with Takeda and other sponsors to monitor the availability and supply of this medicine.
We have approved the supply of overseas-registered alternatives to Vyvanse 30 mg, 50 mg and 60 mg under section 19A of the Therapeutic Goods Act 1989. Up-to-date information about section 19A approvals is available on the Section 19A approvals database.
Information for patients
We understand how important a regular supply of Vyvanse is for patients and their carers, and we appreciate the concern and difficulty these shortages may cause, particularly during the holiday period when specialists may be difficult to access.
There is always someone to talk to about mental health and behavioural concerns. If you or someone close to you is experiencing an emergency, or is at immediate risk of harm, call triple zero (000). To talk to someone now, call Beyond Blue on 1300 22 4636 or Lifeline on 13 11 14.
The HealthDirect website has a full list of mental health resources at www.healthdirect.gov.au/mental-health-resources.
Your pharmacist can advise you about the best way to obtain Vyvanse during these shortages. We have approved access to overseas-registered versions of Vyvanse 30 mg, 50 mg and 60 mg. Details about these products can be found on the Section 19A database. These products are not listed on the Pharmaceutical Benefits Scheme (PBS) and will be more expensive than the Australian product.
If you are unable to fill your Vyvanse prescription, talk to your prescribing doctor, paediatrician or psychiatrist about other treatment options for you or the person you care for.
Information for prescribers
Please consider these shortages when initiating new patients on Vyvanse. If you can limit initiations in this shortage period, this will help preserve available supply for existing patients to maintain continuity of their treatment.
Please refer to this webpage and the Medicine Shortage Reports database for the most up-to-date information.
Pharmacists, patients and carers may contact you to authorise alternative strengths of Vyvanse or substitute medicines to treat their condition. We acknowledge the difficulties involved in the prescribing of controlled drugs and the extra administrative workload these shortages have caused.
We have approved the supply of overseas-registered alternatives to Vyvanse 30 mg, 50 mg and 60 mg under section 19A of the Therapeutic Goods Act 1989. Detailed information about these products is available on the Section 19A approvals database These products are not listed on the Pharmaceutical Benefits Scheme (PBS) and will be more expensive than the Australian product.
Information for pharmacists
Prioritising the dispensing of Vyvanse to ongoing patients where possible will help preserve available supplies for existing patients and maintain continuity of treatment.
Patients and carers may seek help in obtaining Vyvanse from alternative pharmacies or through emergency supply.
Emergency supply for urgent patient need
Takeda Pharmaceuticals has reserved a limited emergency supply of Vyvanse is for instances of urgent patient need. Pharmacists can request emergency stock through Takeda’s online portal.
We have also approved the supply of overseas-registered alternatives to Vyvanse 30 mg, 50 mg and 60 mg under section 19A of the Therapeutic Goods Act 1989. You can contact the approval holder, Medsurge Healthcare, on 1300 788 261 for details about ordering. Detailed information about these products is available on the Section 19A approvals database These products are not listed on the Pharmaceutical Benefits Scheme (PBS) and will be more expensive than the Australian product.
Please note that while the current shortages are expected to end by April 2024, dates may change and will vary for different strengths. We encourage you to check this webpage and the medicine shortage reports database for updates about availability.
We can work with pharmaceutical companies to communicate information about a medicine shortage to health professionals and patients, but we cannot compel companies to increase supply or apply to have their products subsidised on the Pharmaceutical Benefits Scheme (PBS).
Please also keep in mind that we can suggest approaches to manage the supply of medicines during shortages but the TGA does not have the power to regulate the clinical decisions of health professionals.
We will continue to monitor the supply of lisdexamfetamine dimesilate products and work with the suppliers and relevant health professionals to update this advice if needed.